Fibrin clot lysis by tissue plasminogen activator (tpa) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation

Michael T. Leaker, Lu Ann C Brooker, Lesley G. Mitchell, Jeffrey I. Weitz, Ricardo Superina, Maureen E. Andrew*

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Large vessel thrombi can present life-threatening complications following orthotopic liver transplantation (OLT) in pediatric patients. We investigated the thrombolytic response to tissue plasminogen activator (tPA) of stored, pooled plasma (days 4-14 postopera-tively) from 41 patients (mean age 4 years, 9 months) who underwent OLT at the Hospital for Sick Children, Toronto between 1986 and 1990. Trace-labeled fibrin clots were prepared by recalcifying 500-/xl aliquots of patient plasma spiked with 12SI fibrinogen and then incubated at 37°C in patient plasma in the presence or absence of tPA (0.1 or 0.3 mg/ml). At the end of the incubation period, the extent of clot lysis and concentrations of fibrinogen, plasminogen, and α2 antiplasmin were determined. Pooled adult plasma was used as a control. Fibrin clot lysis in OLT plasma was sig-nificantly reduced compared with controls (P<O.Ol). Initial concentrations of plasminogen were significantly reduced in OLT plasma. To determine if the low plasminogen levels limited the thrombolytic effect of tPA, we supplemented OLT plasma with purified plasminogen. Fibrin clots placed in OLT plasma containing adult levels of plasminogen showed a similar lytic response as adults. In summary, the reduced fibrinolytic response of OLT fibrin clots to tPA was due to low concentrations of plasminogen and corrected by plasminogen supplementation.

Original languageEnglish (US)
Pages (from-to)144-147
Number of pages4
JournalTransplantation
Volume60
Issue number2
DOIs
StatePublished - Jul 27 1995

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Fibrin clot lysis by tissue plasminogen activator (tpa) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation'. Together they form a unique fingerprint.

  • Cite this